Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Poor Concordance between Sequential Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in the Diagnosis of Diffuse Interstitial Lung Diseases
Romagnoli, Micaela , Colby, Thomas V. , Berthet, Jean‐Philippe, Gamez, Anne Sophie, Mallet, Jean‐Pierre , Serre, Isabelle, Cancellieri, Alessandra , Solovei, Laurence , Dell’Amore, Andrea , Dolci, Giampiero , Guerrieri, Aldo, Reynaud, Paul, Bommart, Sébastien , Zompatori, Maurizio , Dalpiaz, Giorgia , Trisolini, Rocco , Suehs, Carey , Bourdin, Arnaud , Dell'Amore, Andrea , Dolci, Giampiero , Bommart, Sébastien , Trisolini, Rocco , Suehs, Carey M , Vachier, Isabelle , Molinari, Nicolas , Bourdin, Arnaud , Reynaud, Paul, Nava, Stefano , Vachier, Isabelle , Molinari, Nicolas

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | March 13, 2019 | Volume: 199 | Issue: 10 | Pages: 1249-1256

10.1164/rccm.201810-1947oc | PMID 30864813 Get It

Abstract Rationale The diagnostic concordance between transbronchial lung cryobiopsy (TBLC)—versus surgical lung biopsy (SLB) as the current gold standard—in interstitial lung disease (ILD) cases requiring histology remains controversial. Objectives To assess diagnostic concordance between TBLC and SLB sequentially performed in the same patients, the diagnostic yield of both techniques, and subsequent changes in multidisciplinary assessment (MDA) decisions. Methods A two-center prospective study included patients with ILD with a nondefinite usual interstitial pneumonia pattern (on high-resolution computed tomography scan) confirmed at a first MDA. Patients underwent TBLC immediately followed by video-assisted thoracoscopy for SLB at the same anatomical locations. After open reading of both sample types by local pathologists and final diagnosis at a second MDA (MDA2), anonymized TBLC and SLB slides were blindly assessed by an external expert pathologist (T.V.C.). Kappa-concordance coefficients and percentage agreement were computed for: TBLC versus SLB, MDA2 versus TBLC, MDA2 versus SLB, and blinded pathology versus routine pathology. Measurements and Main Results Twenty-one patients were included. The median TBLC biopsy size (longest axis) was 7 mm (interquartile range, 5–8 mm). SLB biopsy sizes averaged 46.1 ± 13.8 mm. Concordance coefficients and percentage agreement were: TBLC versus SLB: κ = 0.22 (95% confidence interval [CI], 0.01–0.44), percentage agreement = 38% (95% CI, 18–62%); MDA2 versus TBLC: κ = 0.31 (95% CI, 0.06–0.56), percentage agreement = 48% (95% CI, 26–70)%; MDA2 versus SLB: κ = 0.51 (95% CI, 0.27–0.75), percentage agreement = 62% (95% CI, 38–82%); two pneumothoraces (9.5%) were recorded during TBLC. TBLC would have led to a different treatment if SLB was not performed in 11 of 21 (52%) of cases. Conclusions Pathological results from TBLC and SLB were poorly concordant in the assessment of ILD. SLBs were more frequently concordant with the final diagnosis retained at MDA.
Current Practice Trends in Image Guidance During Lumbar and Cervical Transforaminal Epidural Steroid Injections
Vydra, Darrell , Hynes, Alexander, Clements, Nate, Julia, Jonathon, Schneider, Byron J. , Maus, Timothy P. , Cushman, Daniel M. , McCormick, Zachary L. , Nagpal, Ameet

Mayo Clinic

Pain Medicine | March 12, 2019 | Volume: 20 | Issue: 11 | Pages: 2327-2329

10.1093/pm/pnz065 | PMID 30938803 Get It

Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.
Ellis, Paul Anthony, Barrios, Carlos H. , Eiermann, W., Im, Young‐Hyuck , Burris, Howard A. , Strasak, Alexander, Patre, Monika, Perez, Edith A. , Toi, Masakazu , Conte, PierFranco , Martín, Miguel , Pieńkowski, Tadeusz , Pivot, Xavier B.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 507-507

10.1200/jco.2015.33.15_suppl.507 Get It

Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.
Paterson, Alexander , Lew, Danika L., Hayes, Daniel F. , Schubert, Mark, Poznak, Catherine Van , Dees, Elizabeth Claire , Messino, Michael J., Margolis, Jeffrey, Dakhil, Shaker R. , Chew, Helen K. , Livingston, Robert B., Gralow, Julie R. , Barlow, William E. , Stopeck, Alison , Hershman, Dawn L. , Clemons, Mark , Ingle, James N. , Falkson, Carla I. , Elias, Anthony , Hortobágyi, Gabriel N.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 503-503

10.1200/jco.2015.33.15_suppl.503 Get It

Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.
Chanan‐Khan, Asher , Fraser, Graeme , Silva, Rodrigo Santucci, Pylypenko, Halyna, Janssens, Ann , Pristupa, Alexander , Mayer, Jiří , Dilhuydy, Marie‐Sarah, Loscertales, Javier, Avigdor, Abraham, Rule, Simon , Sun, Steven , Mahler, Michelle, Salman, Mariya, Howes, Angela, Cramer, Paula , Demırkan, Fatih , Grosicki, Sebastian , Bartlett, Nancy L. , Hallek, Michael

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: LBA7005-LBA7005

10.1200/jco.2015.33.15_suppl.lba7005 Get It

Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors.
Wilcoxen, Keith, Becker, Marc A., Neff, Christopher, Abkevich, Victor, Jones, Joshua T., Hou, Xiaonan , Wang, Yan , Hartman, Anne‐Renee , AlHilli, Mariam , Gutin, Alexander , Agarwal, Shefali , Timms, Kirsten M. , Neff, Chris, Haluska, Paul

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 5532-5532

10.1200/jco.2015.33.15_suppl.5532 Get It

A randomized, placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with AZD 1775 (MK 1775) in women with recurrent, platinum-resistant epithelial ovarian, primary peritoneal, or Fallopian tube cancers: Trial of
Lheureux, Stéphanie , Weberpals, Johanne I. , Hendrickson, Andrea E. Wahner , Olawaiye, Alexander , Mackay, Helen , Wilson, Michelle , Rodríguez-Freixinós, Víctor, Martín-Lorente, Cristina, Ward, Jacklyn, Chang, Karen, Wang, Lisa , Speers, Vanessa , Karakasis, Katherine, Bowering, Valerie , Chen, Alice P. , Fleming, Gini F. , Braña, Irene , Dhani, Neesha C. , Chang, Karen, Brenton, James D. , Oza, Amit M.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS5613-TPS5613

10.1200/jco.2015.33.15_suppl.tps5613 Get It

Clinical impact of loss of H3K36me3 expression in patients with clear cell renal cell carcinoma.
Swaika, Abhisek, Serie, Daniel, Eckel‐Passow, Jeanette E. , Parker, Alexander S. , Ho, Thai H. , Kapur, Payal , Brugarolas, James , Joseph, Richard W.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 4563-4563

10.1200/jco.2015.33.15_suppl.4563 Get It

Prognostic impact of peripheral blood counts in patients with non-metastatic clear cell renal cell carcinoma.
Hammond, William A. , Hassan, Lauren, Serie, Daniel, Eckel‐Passow, Jeanette E. , Leibovich, Bradley C. , Thompson, R. Houston, Cheville, John C. , Parker, Alexander S. , Hammond, William Adam, Lewis, Daniel, Ho, Thai H. , Joseph, Richard W.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e15590-e15590

10.1200/jco.2015.33.15_suppl.e15590 Get It

Sporadic angiomyolipomas (AMLs) growth kinetics while on everolimus (SAGE).
Kadow, Brian T. , Shuch, Brian , Boorjian, Stephen A. , Rampersaud, Edward N. , McClean, Daniel, Milestone, Barton N., Zibelman, Matthew R. , Smaldone, Marc C., Viterbo, Rosalia, Joshi, Shreyas , Greenberg, Richard E. , Malizzia, Lois, McGowan, Thomas, Geynisman, Daniel M. , Matin, Surena F. , Plimack, Elizabeth R. , Kutikov, Alexander , Chen, David , McGowan, Thomas, Ross, Eric A. , Uzzo, Robert G.

Mayo Clinic

Journal of Clinical Oncology | March 7, 2019 | Volume: 37 | Issue: 7_suppl | Pages: 560-560

10.1200/jco.2019.37.7_suppl.560 Get It

560 Background: Level I evidence exists demonstrating the efficacy of the mTOR inhibitor everolimus (EVE) in decreasing tumor volume of syndromic angiomyolipomas (AMLs) among patients with Tuberous Sclerosis. No prospective data are available regarding the effect of mTOR inhibition on growth kinetics in patients with sporadic AMLs. Methods: We conducted a multi-institutional, prospective, phase 2 trial with an optimal two-stage Simon design in patients presenting with > 3cm sporadic AMLs who were candidates for surgical or percutaneous intervention. Response was defined as ≥25% volumetric reduction of the AML. Planned enrollment was 43 patients to test the null hypothesis at a 5% level of significance with 80% power. Baseline, 4- and 6-month volumetric analysis was performed by dynamic contrast-enhanced MRI (DCE-MRI). Patients received EVE 10mg for four 28-day cycles, at which point EVE was discontinued in those with < 25% volumetric reduction. Those with ≥ 25% volumetric reduction received two additional cycles of EVE. Dose reductions and interruptions were allowed to 5 mg QOD. Conservative stopping rules were established for toxicity, given the benign nature of AMLs. Results: The early stopping rules for both efficacy and toxicity were invoked. We enrolled 20 patients (median age = 68) from 5 centers with 21 sporadic AMLs. 11/20 (55%) patients completed 4 cycles of EVE, while 7/20 (35%) completed 6 cycles. Median days on treatment was 88 (2 cycles). 4/20 (20%) patients were withdrawn due to toxicity, while 8/20 (40%) withdrew due to personal preference. Dose reductions were required in 6/20 (30%) patients, and 5/20 (25%) patients had grade 3 toxicities which resolved upon discontinuation or dose reduction of EVE. At 4-month MRI, 10/16 (62.5%) patients had a ≥25% reduction in volume (mean = 54.1% decrease). At 6-month MRI, 8/12 (66.6%) patients had a ≥25% reduction in volume (mean = 51.5% decrease). Conclusions: EVE was effective in reducing tumor volume in patients with sporadic AMLs but was associated with a high rate of treatment termination due to patient preference or prespecified AEs. Neoadjuvant EVE may be useful in potentiating surgical resection of large or anatomically complex AMLs. Clinical trial information: NCT02539459.